{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:12:20Z","timestamp":1788869540533,"version":"build-2803163510"},"reference-count":79,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.rxeng.2026.501746","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:44:09Z","timestamp":1784807049000},"page":"501746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recommendations for the use of gadolinium-based contrast agents in magnetic resonance imaging of the central nervous system"],"prefix":"10.1016","volume":"68","author":[{"given":"\u00c0.","family":"Rovira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Asenjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Drake-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.F.","family":"Ocete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rxeng.2026.501746_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejro.2023.100503","article-title":"Gadolinium contrast agents- challenges and opportunities of a multidisciplinary approach: literature review","volume":"11","author":"Iyad","year":"2023","journal-title":"Eur J Radiol Open."},{"key":"10.1016\/j.rxeng.2026.501746_bib0010","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.rx.2017.09.007","article-title":"Retention of gadolinium compounds used in magnetic resonance imaging: a critical review and the recommendations of regulatory agencies","volume":"59","author":"Marti-Bonmati","year":"2017","journal-title":"Radiologia."},{"issue":"Suppl 2","key":"10.1016\/j.rxeng.2026.501746_bib0015","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.rxeng.2024.04.004","article-title":"Extracellular gadolinium-based contrast agents","volume":"66","author":"Soler-Fernandez","year":"2024","journal-title":"Radiologia (Engl Ed)."},{"key":"10.1016\/j.rxeng.2026.501746_bib0020","first-page":"1","article-title":"Safety and efficacy of gadobutrol for contrast-enhanced magnetic resonance imaging of the central nervous system: results from a multicenter, double-blind, randomized, comparator study","volume":"8","author":"Gutierrez","year":"2015","journal-title":"Magn Reson Insights."},{"key":"10.1016\/j.rxeng.2026.501746_bib0025","unstructured":"Sociedad Espa\u00f1ola de Radiolog\u00eda M\u00e9dica (SERAM). Posicionamiento de la SERAM respecto a las novedades publicadas sobre seguridad en contrastes con gadolinio [accessed 13 May 2025]. Available from: https:\/\/seram.es\/posicionamiento-de-la-seram-respecto-a-las-novedades-publicadas-sobre-seguridad-en-contrastes-con-gadolinio\/2017."},{"key":"10.1016\/j.rxeng.2026.501746_bib0030","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.neurad.2020.05.008","article-title":"Consensus Guidelines of the French Society of Neuroradiology (SFNR) on the use of Gadolinium-Based Contrast agents (GBCAs) and related MRI protocols in Neuroradiology","volume":"47","author":"Lersy","year":"2020","journal-title":"J Neuroradiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0035","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejrad.2008.01.023","article-title":"Extracellular gadolinium-based contrast media: an overview","volume":"66","author":"Bellin","year":"2008","journal-title":"Eur J Radiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.5603\/PJNNS.a2020.0070","article-title":"Role of gadolinium-based contrast agents in neurological disorders","volume":"54","author":"Golec","year":"2020","journal-title":"Neurol Neurochir Pol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0045","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10534-008-9135-x","article-title":"Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review","volume":"21","author":"Port","year":"2008","journal-title":"Biometals."},{"issue":"Suppl 1","key":"10.1016\/j.rxeng.2026.501746_bib0050","first-page":"21","article-title":"[Gadolinium-based contrast agents for magnetic resonance imaging]","volume":"56","author":"Carrasco Munoz","year":"2014","journal-title":"Radiologia."},{"key":"10.1016\/j.rxeng.2026.501746_bib0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12968-015-0168-3","article-title":"2015 Update on Acute Adverse Reactions to Gadolinium based Contrast Agents in Cardiovascular MR. Large multi-national and multi-ethnical population experience with 37788 patients from the EuroCMR registry","volume":"17","author":"Bruder","year":"2015","journal-title":"J Cardiovasc Magn Reson."},{"key":"10.1016\/j.rxeng.2026.501746_bib0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/PREACCEPT-4280658695831343","article-title":"Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines","volume":"14","author":"Nacif","year":"2012","journal-title":"J Cardiovasc Magn Reson."},{"key":"10.1016\/j.rxeng.2026.501746_bib0065","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/ndt\/gfk062","article-title":"Gadolinium\u2013a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?","volume":"21","author":"Grobner","year":"2006","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.rxeng.2026.501746_bib0070","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1681\/ASN.2006060601","article-title":"Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging","volume":"17","author":"Marckmann","year":"2006","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0075","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Nota informativa de la AEMPS sobre fibrosis sist\u00e9mica nefrog\u00e9nica y contrastes de gadolinio: finalizaci\u00f3n de la revisi\u00f3n en Europa. 2009 [accessed 13 May 2025]. Available from: https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2009\/NI_2009-12_FSN-gadolinio.htm."},{"key":"10.1016\/j.rxeng.2026.501746_bib0080","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00004424-199506000-00008","article-title":"Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats","volume":"30","author":"Tweedle","year":"1995","journal-title":"Invest Radiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0085","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/RLI.0000000000000072","article-title":"Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation","volume":"49","author":"Errante","year":"2014","journal-title":"Invest Radiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0090","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1148\/radiol.13131669","article-title":"High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material","volume":"270","author":"Kanda","year":"2014","journal-title":"Radiology."},{"key":"10.1016\/j.rxeng.2026.501746_bib0095","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1148\/radiol.2015150805","article-title":"Residual or retained gadolinium: practical implications for radiologists and our patients","volume":"275","author":"Kanal","year":"2015","journal-title":"Radiology."},{"key":"10.1016\/j.rxeng.2026.501746_bib0100","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1021\/acschemneuro.8b00044","article-title":"Gadolinium-free contrast agents for magnetic resonance imaging of the central nervous system","volume":"9","author":"Gale","year":"2018","journal-title":"ACS Chem Neurosci."},{"key":"10.1016\/j.rxeng.2026.501746_bib0105","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Riesgo de formaci\u00f3n de dep\u00f3sitos cerebrales asociado a la administraci\u00f3n de agentes de contraste con gadolinio. Recomendaciones del Comit\u00e9 europeo para la evaluaci\u00f3n de riesgos en farmacovigilancia (PRAC). 2017. [accessed 13 May 2025]. Available from: https:\/\/www.aemps.gob.es\/informa\/notasinformativas\/medicamentosusohumano-3\/seguridad-1\/2017\/ni-muh_fv_02-gadolinio\/."},{"key":"10.1016\/j.rxeng.2026.501746_bib0110","unstructured":"European Medicines Agency. Gadolinium-containing contrast agents - referral. 2017 [accessed 13 May 2025]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/gadolinium-containing-contrast-agents."},{"key":"10.1016\/j.rxeng.2026.501746_bib0115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.neurad.2020.03.004","article-title":"Brain MRIs make up the bulk of the gadolinium footprint in medical imaging","volume":"47","author":"Chazot","year":"2020","journal-title":"J Neuroradiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0120","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/jmri.25486","article-title":"Observational study on the safety profile of gadoterate meglumine in 35,499 patients: the SECURE study","volume":"45","author":"Soyer","year":"2017","journal-title":"J Magn Reson Imaging."},{"key":"10.1016\/j.rxeng.2026.501746_bib0125","unstructured":"European Society of Urogenital Radiology (ESUR). Gu\u00edas ESUR sobre agentes de contraste 10.0. 2022 [accessed 13 May 2025]. Available from: https:\/\/www.esur.org\/wp-content\/uploads\/2023\/04\/ESUR_Guidelines_10.0_Final_Version_SPANISH_2022.pdf."},{"key":"10.1016\/j.rxeng.2026.501746_bib0130","unstructured":"Agencia espa\u00f1ola de Medicamentos y Productos Sanitarios. Riesgo de formaci\u00f3n de dep\u00f3sitos cerebrales asociado a la administraci\u00f3n de agentes de contraste con gadolinio: actualizaci\u00f3n de la informaci\u00f3n. 2017 [accessed 13 May 2025]. Available from: http:\/\/aemps.gob.es\/informa\/notasinformativas\/medicamentosusohumano-3\/seguridad-1\/2017\/ni-muh_fv_07-2017-gadolinio\/."},{"key":"10.1016\/j.rxeng.2026.501746_bib0135","unstructured":"Ficha t\u00e9cnica Gadovist 1 mmol\/ml soluci\u00f3n inyectable en vial [accessed 13 May 2025]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/63535\/FichaTecnica_63535.html."},{"key":"10.1016\/j.rxeng.2026.501746_bib0140","unstructured":"Ficha t\u00e9cnica Dotarem 0,5mmol\/ml [accessed 13 May 2025]. Available from: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/67489\/67489_ft.pdf."},{"key":"10.1016\/j.rxeng.2026.501746_bib0145","unstructured":"Ficha T\u00e9cnica ProHance 279,3mg\/ml soluci\u00f3n inyectable [accessed 13 May 2025]. Available from: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/60377\/60377_ft.pdf."},{"key":"10.1016\/j.rxeng.2026.501746_bib0150","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3390\/jcm13082193","article-title":"Safe and informed use of gadolinium-based contrast agent in body magnetic resonance imaging: where we were and where we are","volume":"13","author":"Iacobellis","year":"2024","journal-title":"J Clin Med."},{"key":"10.1016\/j.rxeng.2026.501746_bib0155","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jama.2016.12126","article-title":"Association between MRI exposure during pregnancy and fetal and childhood outcomes","volume":"316","author":"Ray","year":"2016","journal-title":"JAMA."},{"key":"10.1016\/j.rxeng.2026.501746_bib0160","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030163","article-title":"Gadolinium-based contrast agents for imaging of the central nervous system: a multicenter European prospective study","volume":"101","author":"Heshmatzadeh Behzadi","year":"2022","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.rxeng.2026.501746_bib0165","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00330-010-1805-8","article-title":"High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review","volume":"20","author":"Giesel","year":"2010","journal-title":"Eur Radiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0170","doi-asserted-by":"crossref","first-page":"266","DOI":"10.32440\/ar.2024.141.03.rev07","article-title":"Retos para entender la relevancia del dep\u00f3sito de gadolinio tras su administraci\u00f3n en resonancia magn\u00e9tica","volume":"141","author":"Frontera Valero","year":"2024","journal-title":"An RANM."},{"key":"10.1016\/j.rxeng.2026.501746_bib0175","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00234-024-03305-2","article-title":"Go Green in Neuroradiology: towards reducing the environmental impact of its practice","volume":"66","author":"Rovira","year":"2024","journal-title":"Neuroradiology."},{"key":"10.1016\/j.rxeng.2026.501746_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2020.144846","article-title":"Comprehensive review on iodinated X-ray contrast media: Complete fate, occurrence, and formation of disinfection byproducts","volume":"769","author":"Sengar","year":"2021","journal-title":"Sci Total Environ."},{"key":"10.1016\/j.rxeng.2026.501746_bib0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2021.146273","article-title":"What do we know about the ecotoxicological implications of the rare earth element gadolinium in aquatic ecosystems?","volume":"781","author":"Trapasso","year":"2021","journal-title":"Sci Total Environ."},{"key":"10.1016\/j.rxeng.2026.501746_bib0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.envpol.2024.124740","article-title":"Anthropogenic gadolinium contaminations in the marine environment and its ecological implications","volume":"359","author":"Zhang","year":"2024","journal-title":"Environ Pollut."},{"key":"10.1016\/j.rxeng.2026.501746_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.watres.2020.115966","article-title":"Anthropogenic gadolinium in freshwater and drinking water systems","volume":"182","author":"Brunjes","year":"2020","journal-title":"Water Res."},{"key":"10.1016\/j.rxeng.2026.501746_bib0200","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/geosciences9020093","article-title":"Gadolinium as an emerging microcontaminant in water resources: threats and opportunities","volume":"9","author":"Ebrahimi","year":"2019","journal-title":"Geosciences."},{"key":"10.1016\/j.rxeng.2026.501746_bib0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.etap.2025.104673","article-title":"Assessing the toxicity of gadolinium in freshwater and marine ecosystems: effects across trophic levels","volume":"115","author":"Mossotto","year":"2025","journal-title":"Environ Toxicol Pharmacol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0210","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.neurad.2020.03.006","article-title":"Gadolinium footprint: cradle to cradle?","volume":"47","author":"Ognard","year":"2020","journal-title":"J Neuroradiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0215","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/RLI.0000000000001025","article-title":"A comprehensive overview of the efficacy and safety of gadopiclenol: a new contrast agent for MRI of the CNS and body","volume":"59","author":"Hao","year":"2024","journal-title":"Invest Radiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0220","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/RLI.0000000000001028","article-title":"AI as a new frontier in contrast media research: bridging the gap between contrast media reduction, the contrast-free question and new application discoveries","volume":"59","author":"Haubold","year":"2024","journal-title":"Invest Radiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0225","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/RLI.0000000000001137","article-title":"Metastasis detection using true and artificial T1-weighted postcontrast images in brain MRI","volume":"60","author":"Haase","year":"2025","journal-title":"Invest Radiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0230","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/RLI.0000000000000811","article-title":"Can deep learning replace gadolinium in neuro-oncology?: A reader study","volume":"57","author":"Ammari","year":"2022","journal-title":"Invest Radiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0235","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/jmri.27731","article-title":"Dose-lowering in contrast-enhanced MRI of the central nervous system: a retrospective, parallel-group comparison using gadobenate dimeglumine","volume":"54","author":"DeLano","year":"2021","journal-title":"J Magn Reson Imaging."},{"key":"10.1016\/j.rxeng.2026.501746_bib0240","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/RLI.0000000000001041","article-title":"Clinical efficacy of gadobutrol: review of over 25 years of use exceeding 100 million administrations","volume":"59","author":"Endrikat","year":"2024","journal-title":"Invest Radiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0245","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s003300000493","article-title":"Use of half-dose gadolinium-enhanced MRI and magnetization transfer saturation in brain tumors","volume":"11","author":"Haba","year":"2001","journal-title":"Eur Radiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0250","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/j.wneu.2019.11.051","article-title":"Noncontrast T2-weighted magnetic resonance imaging sequences for long-term monitoring of asymptomatic convexity meningiomas","volume":"135","author":"He","year":"2020","journal-title":"World Neurosurg."},{"key":"10.1016\/j.rxeng.2026.501746_bib0255","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2214\/AJR.21.25924","article-title":"Clinical efficacy of reduced-dose gadobutrol versus standard-dose gadoterate for contrast-enhanced MRI of the CNS: an International Multicenter Prospective Crossover Trial (LEADER-75)","volume":"217","author":"Liu","year":"2021","journal-title":"AJR Am J Roentgenol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0260","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/RLI.0000000000000944","article-title":"Efficacy and safety of gadopiclenol for contrast-enhanced MRI of the central nervous system: the PICTURE Randomized Clinical Trial","volume":"58","author":"Loevner","year":"2023","journal-title":"Invest Radiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0265","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1007\/s00247-018-4154-4","article-title":"Surveillance magnetic resonance imaging for isolated optic pathway gliomas: is gadolinium necessary?","volume":"48","author":"Maloney","year":"2018","journal-title":"Pediatr Radiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0270","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3174\/ajnr.A5316","article-title":"Comparison of gadoterate meglumine and gadobutrol in the MRI diagnosis of primary brain tumors: a double-blind randomized controlled intraindividual crossover study (the REMIND study)","volume":"38","author":"Maravilla","year":"2017","journal-title":"AJNR Am J Neuroradiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0275","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3174\/ajnr.A4154","article-title":"Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study)","volume":"36","author":"Maravilla","year":"2015","journal-title":"AJNR Am J Neuroradiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0280","article-title":"Reducing gadolinium exposure in patients undergoing monitoring for meningiomas","volume":"15","author":"Sathraju","year":"2023","journal-title":"Cureus."},{"key":"10.1016\/j.rxeng.2026.501746_bib0285","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3174\/ajnr.A3033","article-title":"Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study)","volume":"33","author":"Seidl","year":"2012","journal-title":"AJNR Am J Neuroradiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0290","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3174\/ajnr.A4468","article-title":"The benefits of high relaxivity for brain tumor imaging: results of a multicenter intraindividual crossover comparison of gadobenate dimeglumine with gadoterate meglumine (The BENEFIT Study)","volume":"36","author":"Vaneckova","year":"2015","journal-title":"AJNR Am J Neuroradiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0295","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.neurad.2023.08.003","article-title":"Is non-contrast MRI sufficient to detect meningioma residue after surgery?","volume":"51","author":"Alonso","year":"2024","journal-title":"J Neuroradiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0300","first-page":"209","article-title":"Evaluation of the necessity of contrast in the follow-up MRI of schwannomas","volume":"17","author":"Bayraktaro\u011flu","year":"2011","journal-title":"Diagn Interv Radiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0305","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3174\/ajnr.A7170","article-title":"Is contrast medium really needed for follow-up MRI of untreated intracranial meningiomas?","volume":"42","author":"Boto","year":"2021","journal-title":"AJNR Am J Neuroradiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0310","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/lary.26589","article-title":"MRI surveillance of vestibular schwannomas without contrast enhancement: clinical and economic evaluation","volume":"128","author":"Coelho","year":"2018","journal-title":"Laryngoscope."},{"key":"10.1016\/j.rxeng.2026.501746_bib0315","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3174\/ajnr.A8375","article-title":"Comparative evaluation of lower gadolinium doses for MR imaging of meningiomas: how low can we go?","volume":"45","author":"Dowers","year":"2024","journal-title":"AJNR Am J Neuroradiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0320","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1093\/neuros\/nyx510","article-title":"Congress of neurological surgeons systematic review and evidence-based guidelines on the role of imaging in the diagnosis and management of patients with vestibular schwannomas","volume":"82","author":"Dunn","year":"2018","journal-title":"Neurosurgery."},{"key":"10.1016\/j.rxeng.2026.501746_bib0325","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1017\/S0022215118001342","article-title":"Non-contrast magnetic resonance imaging for monitoring patients with acoustic neuroma","volume":"132","author":"Forgues","year":"2018","journal-title":"J Laryngol Otol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0330","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0335","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1097\/MAO.0000000000001881","article-title":"Is an intravenous injection of gadolinium really necessary for intralabyrinthine schwannomas MR examination?","volume":"39","author":"Karol","year":"2018","journal-title":"Otol Neurotol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0340","doi-asserted-by":"crossref","first-page":"e2769","DOI":"10.1002\/brb3.2769","article-title":"Characterization of meningiomas with synthetic imaging","volume":"12","author":"Ludovichetti","year":"2022","journal-title":"Brain Behav."},{"key":"10.1016\/j.rxeng.2026.501746_bib0345","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/jon.12926","article-title":"Intracranial meningioma surveillance using volumetrics from T2-weighted MRI","volume":"32","author":"Raban","year":"2022","journal-title":"J Neuroimaging."},{"key":"10.1016\/j.rxeng.2026.501746_bib0350","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clinimag.2018.10.014","article-title":"Can unenhanced brain magnetic resonance imaging be used in routine follow up of meningiomas to avoid gadolinium deposition in brain?","volume":"53","author":"Rahatli","year":"2019","journal-title":"Clin Imaging."},{"key":"10.1016\/j.rxeng.2026.501746_bib0355","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1053089","article-title":"Predicting the grade of meningiomas by clinical-radiological features: a comparison of precontrast and postcontrast MRI","volume":"12","author":"Yao","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0360","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/MAO.0000000000002416","article-title":"Non-contrast magnetic resonance imaging for diagnosis and monitoring of vestibular schwannomas: a systematic review and meta-analysis","volume":"40","author":"Kim","year":"2019","journal-title":"Otol Neurotol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0365","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1148\/radiology.180.3.1871293","article-title":"Pituitary adenoma: correlation of half-dose gadolinium-enhanced MR imaging with surgical findings in 26 patients","volume":"180","author":"Davis","year":"1991","journal-title":"Radiology."},{"key":"10.1016\/j.rxeng.2026.501746_bib0370","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neurad.2022.08.003","article-title":"Is systematic Gadolinium injection relevant during MRI follow-up for non-functioning pituitary macroadenomas?","volume":"50","author":"Villemaire","year":"2023","journal-title":"J Neuroradiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0375","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3174\/ajnr.A7554","article-title":"Do we need gadolinium-based contrast agents for routine MRI surveillance of unoperated pituitary macroadenoma?","volume":"43","author":"Alali","year":"2022","journal-title":"AJNR Am J Neuroradiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0380","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jrr\/rrs053","article-title":"Usefulness of double dose contrast-enhanced magnetic resonance imaging for clear delineation of gross tumor volume in stereotactic radiotherapy treatment planning of metastatic brain tumors: a dose comparison study","volume":"54","author":"Subedi","year":"2013","journal-title":"J Radiat Res."},{"key":"10.1016\/j.rxeng.2026.501746_bib0385","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3174\/ajnr.A5253","article-title":"Cumulative dose of macrocyclic gadolinium-based contrast agent improves detection of enhancing lesions in patients with multiple sclerosis","volume":"38","author":"Rovira","year":"2017","journal-title":"AJNR Am J Neuroradiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0390","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00330-023-10151-y","article-title":"Use of gadolinium-based contrast agents in multiple sclerosis: a review by the ESMRMB-GREC and ESNR Multiple Sclerosis Working Group","volume":"34","author":"Rovira","year":"2024","journal-title":"Eur Radiol."},{"key":"10.1016\/j.rxeng.2026.501746_bib0395","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1177\/0271678X20914537","article-title":"Comparison of Tmax values between full- and half-dose gadolinium perfusion studies","volume":"41","author":"Christensen","year":"2021","journal-title":"J Cereb Blood Flow Metab."}],"container-title":["Radiolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173510726001059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173510726001059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:49:25Z","timestamp":1788868165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173510726001059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2173510726001059"],"URL":"https:\/\/doi.org\/10.1016\/j.rxeng.2026.501746","relation":{},"ISSN":["2173-5107"],"issn-type":[{"value":"2173-5107","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for the use of gadolinium-based contrast agents in magnetic resonance imaging of the central nervous system","name":"articletitle","label":"Article Title"},{"value":"Radiolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rxeng.2026.501746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rx.2025.501746","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of SERAM.","name":"copyright","label":"Copyright"}],"article-number":"501746"}}